Skip to Content
  • Avandia: Trouble, Run Head to Head

    Avandia (rosiglitazone) has been under suspicion for the last couple of years, after data appeared suggesting a higher rate of cardiovascular problems with its… Read More
  • Fructose In The Brain?

    Let’s talk sugar, and how you know if you’ve eaten enough of it. Just in time for Halloween! This is a field I’ve done drug discovery for in the past, and… Read More
  • Taranabant Is No More

    Merck has taken a step that many people have been expecting, and announced that they are no longer developing taranabant, their cannabinoid antagonist (or is it… Read More
  • Metabolic Hope Springs Eternal

    Now, if I were still doing metabolic disease work, I’d be all over this target: CAMKK2, which is mercifully short for “Ca2+/calmodulin-dependent pro… Read More
  • Alli: “Underwhelming”

    About a year ago, I wrote about GSK’s attempt to sell the lipase inhibitor orlistat over the counter as Alli: “So my forecast for Alli is strong sal… Read More
  • Merck Bails on Natural Products

    Every few years, you hear talk of a renaissance in natural products-based drug discovery. Well, this news should postpone the next round of optimism for a bit l… Read More
  • Why Buy, Anyway?

    I don’t want to say that this is a trend, but I notice that GSK is saying that they’re going to leave Sirtris more or less alone as well (as Takeda has said… Read More
Page 10 of 15« First...89101112...Last »